Coordenadoria Geral da Universidade
Repositorio da Producao Cientifica e Intelectual da UnicampNot a member yet
169449 research outputs found
Sort by
Comparative study between fast and slow induction of propofol given by target‐controlled infusion: expected propofol concentration at the effect site. Randomized controlled trial
No full textJustificativa e objetivo: estudos mostraram que a taxa de infusão de propofol pode influenciar na concentração prevista de propofol no local de ação (Ce). O objetivo deste estudo foi avaliar a Ce prevista pelo modelo farmacocinético de Marsh (ke0 0,26 min−1) na perda da consciência durante indução rápida ou lenta. Método: participaram deste estudo 28 pacientes, divididos aleatoriamente em dois grupos iguais. No grupo indução lenta (L), foram induzidos com propofol em infusão alvo‐controlada (IAC) plasmática, modelo farmacocinético de Marsh (ke0 0,26 min−1), com concentração alvo (Ca) em 2,0 μg.ml−1. Quando a concentração de propofol prevista no local de ação (Ce) atingia metade do valor da Ca, aumentava‐se a Ca para Ca anterior + 1 μg.ml−1. Assim sucessivamente até o momento da perda da consciência do paciente. No grupo indução rápida (R), os pacientes foram induzidos com propofol em IAC plasmática com Ca em 6,0 μg.ml−1 e aguardava‐se a perda da consciência do paciente. Resultados: no grupo indução rápida, a Ce na perda da consciência foi significativamente mais baixa em relação ao grupo de indução lenta (1,67 ± 0,76 e 2,50 ± 0,56 μg.ml−1, respectivamente, p = 0,004). Conclusão: a concentração prevista de propofol no local de ação durante a perda da consciência é diferente numa indução rápida e numa indução lenta, até com o mesmo modelo farmacocinético de propofol e a mesma constante de equilíbrio entre o plasma e o local de ação65299103Background and objective: studies have shown that rate of propofol infusion may influence the predicted propofol concentration at the effect site (Es). The aim of this study was to evaluate the Es predicted by the Marsh pharmacokinetic model (ke0 0.26min-1) in loss of consciousness during fast or slow induction. Method: the study included 28 patients randomly divided into two equal groups. In slow induction group (S), target-controlled infusion (TCI) of propofol with plasma, Marsh pharmacokinetic model (ke0 0.26min-1) with target concentration (Tc) at 2.0-μg.mL-1 were administered. When the predicted propofol concentration at the effect site (Es) reached half of Es value, Es was increased to previous Es + 1μg.mL-1, successively, until loss of consciousness. In rapid induction group (R), patients were induced with TCI of propofol with plasma (6.0μg.ml-1) at Es, and waited until loss of consciousness. Results: in rapid induction group, Tc for loss of consciousness was significantly lower compared to slow induction group (1.67±0.76 and 2.50±0.56μg.mL-1, respectively, p=0.004). Conclusion: the predicted propofol concentration at the effect site for loss of consciousness is different for rapid induction and slow induction, even with the same pharmacokinetic model of propofol and the same balance constant between plasma and effect sitesem informaçã
Numerical methods and fuzzy parameters : an environmental impact assessment in aquatic systems
No full textsem informaçãoThis paper proposes to analyze the dispersion of pollutants in aquatic systems, solving the advection-diffusion equation using numerical methods and fuzzy sets. For solution, numerical approximations were adopted, based on the finite element method for th36415171528sem informaçãosem informaçãosem informaçã
Well-posedness of the vector advection equations by stochastic perturbation
No full textFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOA linear stochastic vector advection equation is considered. The equation may model a passive magnetic field in a random fluid. The driving velocity field is a integrable to a certain power, and the noise is infinite dimensional. We prove that, thanks to182277301FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO2015/04723-2460713/2014-
Non-local conservation law from stochastic particle systems
No full textCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOWe consider an interacting particle system in (Formula presented.) modelled as a system of N stochastic differential equations. The limiting behaviour as the size N grows to infinity is achieved as a law of large numbers for the empirical density process30416611682CNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO460713/2014-02015/04723-22015/07278-
Estudo de biodisponibilidade relativa de duas formulações de levofioxacino em voluntários sadios de ambos os sexos
No full textThe study was conducted to compare the bioavailability of two formulations of levofloxacin 500 mg tablet (levofloxacin of Aché S/A test formulation and Tavanic® from Sanofi-Aventis Farmacêutica Ltda. reference formulation, Brazil) in 28 volunteers both sexes. This was an open, randomized, two-sequence, two-period, crossover single dose two treatments, in which a group of volunteers received the test formulation and the other reference formulation. Blood samples were obtained throughout a 48 hours interval. The levofloxacin concentrations were determined by mass spectrometry (HPLC-MS-MS) using Ciprofloxacin as internal standard. From the data obtained, calculate the following pharmacokinetic parameters: AUC0-t, AUC0-" and Cmax. The geometric mean of levofloxacin /Tavanic® 500 mg were 107.00% for AUC0-t, 107.07% for AUC0-" and 106.70% for Cmax. The 90% confidence intervals were 103.06-111.09%, 103.16-111.13% and 96.27-118.27%, respectively. Since the confidence intervals 90% for Cmax and AUC0-t was within the range 80-125% proposed by the FDA and ANVISA (National Agency of Sanitary Surveillance in Brazil), it is concluded that the tablet of Levofloxacin 500 mg was bioequivalent to Tavanic® tablet of 500 mg and thus the test product may be considered interchangeable in medical practice7111sem informaçã
Souza AN, Pitanguy J. Saúde, corpo e sociedade. Rio de Janeiro: Editora UFRJ; 2014.
No full textSem informação205750951
Perda de peso excessiva em recém‐nascidos a termo amamentados exclusivamente ao seio materno em um Hospital Amigo da Criança
No full textTo determine the risk factors for weight loss over 8% in full‐term newborns at postpartum discharge from a Baby Friendly Hospital. Methods The cases were selected from a cohort of infants belonging to a previous study. Healthy full‐term newborns with birth weight ≥2.000g, who were exclusively breastfed, and excluding twins and those undergoing phototherapy as well as those discharged after 96 hours of life, were included. The analyzed maternal variables were maternal age, parity, ethnicity, type of delivery, maternal diabetes, gender, gestational age and appropriate weight for age. Adjusted multiple and univariate Cox regression analyses were used, considering as significant p8% were caesarean delivery and older maternal age. At the adjusted multiple regression analysis, the model to explain the weight loss was cesarean delivery (relative risk: 2.27 and 95% of confidence interval: 1.54 to 3.35). Conclusions The independent predictor for weight loss >8% in exclusively breastfed full‐term newborns in a Baby‐Friendly Hospital was the cesarean delivery. It is possible to reduce the number of cesarean sections to minimize neonatal excessive weight loss and the resulting use of infant formula during the first week of life.34328128
Genomics, transcriptomics, and beyond: the fifteen years of cacao’s witches’ broom disease genome project
No full textCacao production in Brazil was severely affected by the outbreak of witches’ broom disease (WBD) in the late 1980s. WBD is caused by the basidiomycete fungus Moniliophthora perniciosa, a hemibiotrophic pathogen that displays an uncommonly long-lasting biotrophic stage during which the host cacao suffers intense morphologic alterations in the infected shoots, giving rise to “green brooms.” Two months after infection, the fungus becomes necrotrophic resulting in the necrosis and destruction of the infected tissues that turn into a “dry broom.” During the last 15 years, the knowledge of this devastating and intriguing disease has been growing due to initiatives such as the WBD genome project. By using genomics and transcriptomics as tools to obtain insights about this disease, the WBD project has been elucidating the biochemistry and physiology of both plant host and pathogen, paving the way for practical applications to combat the fungus. In this chapter we present an overview of progress in the understanding of M. perniciosa genetics and the molecular mechanisms governing WBD, provide a model for the M. perniciosa–cacao interaction, and point to new directions to fight this disease.17921
Co-constyruction of the healthcare autonomy for person with diabetes || Co-construcción de la autonomía del cuidado de la persona con diabetes
No full textTrata-se de uma pesquisa qualitativa sobre a coconstrução da autonomia do cuidado da pessoa com diabetes, por meio das reflexões dos usuários diabéticos e profissionais de saúde de uma equipe de ambulatório especializado público, localizado num município de médio porte no sul do Brasil. Os dados foram coletados por intermédio de entrevistas semiestruturadas de pessoas com diabetes, profissionais de saúde e uma Roda de Conversa com os profissionais sobre as falas destes usuários. Os dados obtidos foram submetidos à análise de conteúdo, especificamente, a análise temática. A escuta, a clínica ampliada e a cogestão se afirmaram como estratégias potentes para compreender o viver e o lidar com diabetes como um processo singular e compartilhado entre adoecidos e profissionais de saúde, onde a doença faça parte da vida e não a vida parte da doença.2059941951This is a qualitative research on the co-construction of the autonomy of care for individuals with diabetes through the reflections of diabetic users and health professionals in a team of a specialized public clinic, located in a medium-sized municipality in southern Brazil. Data were collected through semi-structured interviews of people with diabetes, health professionals and a conversation meeting with professionals about the discourses of these users. The analysis was guided by content analysis, specifically thematic analysis. Listening, expanded clinical approach and co-management proved to be key strategies to understand and live and copel with diabetes as a singular process by creating strategies shared between disease bearers and health professionals, where the disease is part of life, not life part of the disease || Se trata de una investigación cualitativa sobre la co-construcción de la autonomía de la persona con diabetes por medio de las reflexiones de los usuarios diabéticos y profesionales de la salud de un equipo de una clínica pública especializada, ubicada en un municipio de tamaño medio en el sur de Brasil. Los datos fueron recolectados a través de entrevistas semiestructuradas a personas con diabetes, profesionales de la salud y una charla con profesionales sobre las narrativas de estos usuarios. El marco analítico de la presente investigación se basó en el análisis de contenido, específicamente el análisis temático. El acto de oír, la co-gestión y la clínica ampliada se colocaron como estrategias clave para entender y vivir con diabetes como un proceso singular que es posible alcanzar mediante la creación de estrategias compartidas entre los enfermos y los profesionales de salud, donde la enfermedad sea parte de la vida, y no la vida de la enfermedad
Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: A systematic review and meta-analysis
No full textChemotherapymay result in a detrimental effect on ovarian function and fertility in premenopausal women undergoing treatment for early-stage breast cancer (EBC). To minimize risk of harm to ovarian function and fertility for patients in this setting, careful considerations should be made. Gonadotropin-releasing hormone agonists (GnRHa) have been suggested as an alternative to prevent the loss of ovarian function due to exposure to cytotoxic agents, but GnRHa use for ovarian protection in EBC patients is not fully resolved. Objective: To determine the effectiveness of GnRHa administered concurrently with chemotherapy for ovarian function preservation. Data Sources: PubMed, SCOPUS, and Cochrane databases were searched for studies published between January 1975 and March 2015. The abstracts of the American Society of Clinical Oncology Annual Meeting between 1995 and 2014 and the San Antonio Breast Cancer Symposium between 2009 and 2014 were searched as well. Study Selection: Prospective, randomized, clinical trials addressing the role of ovarian suppression with GnRHa in preventing early ovarian dysfunction in premenopausal women undergoing treatment for EBC were selected. Data Extraction and Synthesis: Data extractionwas performed independently by 2 authors. Themethodology and the risk of bias were assessment based on the description of randomization method, withdrawals, and blinding process. Main Outcomes and Measures: Rate of resumption of regular menses after a minimal follow-up period of 6 months following chemotherapy was used as a surrogate to assess the incidence of ovarian dysfunction. Additional secondary outcomes included hormone levels and number of pregnancies. Risk ratio estimates were calculated based on the number of evaluable patients. Analyses were conducted using a random effect model. Results: Seven studies were included in this analysis, totaling 1047 randomized patients and 856 evaluable patients. The use of GnRHa was associated with a higher rate of recovery of regular menses after 6 months (odds ratio [OR], 2.41; 95%CI, 1.40-4.15; P = .002) and at least 12 months (OR, 1.85; 95%CI, 1.33-2.59; P < .001) following the last chemotherapy cycle. The use of GnRHa was also associated with a higher number of pregnancies (OR, 1.85; 95%CI, 1.02-3.36; P = .04), although this outcome was not uniformly reported and fertility or rate of pregnancy was not the primary outcome in any of the trials. Conclusions and Relevance: Gonadotropin-releasing hormone agonists given with chemotherapy was associated with increased rates of recovery of regular menses in this meta-analysis. Evidence was insufficient to assess outcomes related to GnRHa and ovarian function and fertility and needs further investigation. Copyright © 2016 American Medical Association.21657